Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574349 | 1.00 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 | |
| SCHEMBL7528438 | 0.93 | MAPK1 (0.59) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 | |
| SCHEMBL27625609 | 0.91 | MAPK1 (0.57) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 | |
| SCHEMBL7528433 | 0.88 | KDM4E (0.58) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 | |
| Ethyl Acetate SCHEMBL575043 | 0.87 | MAPK1 (0.53) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 | |
| SCHEMBL7443540 | 0.87 | MAPK1 (0.53) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 | |
| SCHEMBL13320210 | 0.87 | MAPK1 (0.61) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 | |
| SCHEMBL989845 | 0.84 | GRM5 (0.62) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 | |
| SCHEMBL27892719 | 0.82 | HDAC1 (0.55) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 | |
| SCHEMBL28243051 | 0.82 | HDAC1 (0.55) | MAPK1KDM4EL3MBTL1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079874-A | Method and device for synthesizing etoricoxib key intermediate MMPE through continuous flow | — | 2026-05-26 | — | — | CN | claimed |
| CN-119285609-A | Preparation method of chiral 6-methyl nicotine | 恒信永基科技(深圳)有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-118853791-A | Method for preparing (S) -6-methyl nicotine by reduction mode | 重庆博腾制药科技股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118852102-A | Method for synthesizing high optical purity (S) -6-methyl nicotine | 重庆博腾制药科技股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-115611857-B | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海伍夫科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-115894143-B | Palladium catalyzed double ligand unguided preparation method for deuterated aromatic compound | 宁波萃英化学技术有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117658893-A | Method for carrying out cis-trans selective hydrogenation on 2, 5-substituted pyridine derivative by utilizing micro-packed bed | 南京药石科技股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-113603684-B | 1,2, 4-oxadiazole Nrf2 activator-tac Lin Pinge product and preparation method and application thereof | 中国药科大学 | 2023-12-19 | — | — | CN | claimed |
| CN-114195759-B | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海零诺生物科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-114437031-B | Synthesis method of 6-methyl nicotine | 深圳市真味生物科技有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-20120122914-A1 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCE P.L.A.CHINA (CN) | 2012-05-17 | — | — | US | claimed |
| EP-2417973-A1 | SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO Ý4, 3-b¨INDOLE DERIVATIVE AND PREPARATION METHOD OF DERIVATIVE | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 2012-02-15 | — | — | EP | claimed |
| EP-1725537-B1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-13 | — | — | EP | claimed |
| CN-101857567-A | Preparation method of high-purity 2,5-dipicolinic acid | ZHEJIANG DINGLONG CHEMICALS CO LTD | 2010-10-13 | — | — | CN | claimed |
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| EP-1108711-B1 | A method for producing a heterocyclic nitrile | KOEI CHEMICAL CO (JP) | 2003-09-10 | — | — | EP | claimed |
| WO-2001029003-A1 | PROCESS FOR THE PREPARATION OF 1-(6-METHYLPYRIDIN-3-YL)-2-(4-METHYLTHIOPHENYL)-ETHANONE AND ITS USE IN THE SYNTHESIS OF DIARYLPYRIDINES | ZAMBON GROUP S.P.A. (IT) | 2001-04-26 | — | — | WO | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122914-A1 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | HTT, HTR5A, HTR3B | MAPK1 3494/4885KDM4E 895/4885L3MBTL1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.